liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control
Linköping University, Department of Clinical and Experimental Medicine, Cell Biology. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Local Health Care Services in Central Östergötland, Department of Acute Internal Medicine.
Linköping University, Department of Medical and Health Sciences, Internal Medicine. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Centre for Medicine, Department of Endocrinology and Gastroenterology UHL.
Borensberg Health Centre, Linköping.
Linköping University, Department of Clinical and Experimental Medicine, Cell Biology. Linköping University, Faculty of Health Sciences.
Show others and affiliations
2009 (English)In: Acta Diabetologica, ISSN 0940-5429, E-ISSN 1432-5233, Vol. 46, no 1, 35-42 p.Article in journal (Refereed) Published
Abstract [en]

Our aim was to study, at the same glycemic control, how treatment with either the insulin secretagogue repaglinide or exogenous insulin aspart affects endogenous insulin secretion, plasma insulin and IAPP (islet amyloid polypeptide) levels, GH-IGF (growth hormone-insulin-like growth factor) axis and plasma lipoprotein concentrations in patients with type 2 diabetes. Five patients, age 65.0 +/- A 4.1 years (mean +/- A SE), body weight 82.5 +/- A 5.0 kg, BMI (body mass index) 27.7 +/- A 1.5 kg/m(2) were treated for 10 weeks with repaglinide or insulin aspart in a randomized, cross-over study. At the end of each treatment a 24-h metabolic profile was performed. Blood glucose, C-peptide, free human insulin, free total (human and analogue) insulin, proinsulin, IAPP, IGF-I, IGFBP-1 (IGF binding protein-1), GHBP (growth hormone binding protein) and plasma lipoprotein concentrations were measured. Similar 24-h blood glucose profiles were obtained with repaglinide and insulin aspart treatment. During the repaglinide treatment, the meal related peaks of C-peptide and free human insulin were about twofold higher than during treatment with insulin aspart. Proinsulin, GHBP were higher and IAPP levels tended to be higher during repaglinide compared to insulin aspart. Postprandial plasma total cholesterol, triglycerides and apolipoprotein B concentrations were higher on repaglinide than on insulin aspart treatment. Our results show that, at the same glycemic control, treatment with exogenous insulin aspart in comparison with the insulin secretagogue repaglinide result in a lower endogenous insulin secretion, and a tendency towards a less atherogenic postprandial lipid profile.

Place, publisher, year, edition, pages
2009. Vol. 46, no 1, 35-42 p.
Keyword [en]
Insulin secretagogue, Insulin-like growth factor, Lipoprotein
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:liu:diva-16891DOI: 10.1007/s00592-008-0055-6ISI: 000263001000005OAI: oai:DiVA.org:liu-16891DiVA: diva2:174438
Note

The original publication is available at www.springerlink.com: Ioana Simona Chisalita, Torbjörn Lindström, Pär Eson Jennersjö, Johan Paulsson, Gunilla Westermark, Anders Olsson and Hans Arnqvist, Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control, 2009, ACTA DIABETOLOGICA, (46), 1, 35-42. http://dx.doi.org/10.1007/s00592-008-0055-6 Copyright: Springer -- Verlag http://www.springerlink.com/

Available from: 2009-02-26 Created: 2009-02-20 Last updated: 2017-01-19Bibliographically approved

Open Access in DiVA

fulltext(371 kB)923 downloads
File information
File name FULLTEXT01.pdfFile size 371 kBChecksum SHA-512
bd63406919e6126aef9e02b560e072e703fc970e58c2c633ecbb39dcb4d69a5032c98460c5e0a8af3d63ace2f93f26aaf853ffa97fd07582865ca6348bc93026
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records BETA

Chisalita, Simona IoanaLindström, TorbjörnPaulsson, JohanWestermark, GunillaOlsson, AndersArnqvist, Hans

Search in DiVA

By author/editor
Chisalita, Simona IoanaLindström, TorbjörnPaulsson, JohanWestermark, GunillaOlsson, AndersArnqvist, Hans
By organisation
Cell BiologyFaculty of Health SciencesDepartment of Acute Internal MedicineInternal MedicineDepartment of Endocrinology and Gastroenterology UHL
In the same journal
Acta Diabetologica
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar
Total: 923 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 364 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf